Every Form 4 that Recursion Pharmaceuticals, Inc. (RXRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RXRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RXRX filings page.
Recursion Pharmaceuticals director Dean Y. Li received a new equity grant. On 01/02/2026, he was awarded 2,381 shares of Class A Common Stock at a price of $0. The filing states these shares were issued under the company’s Outside Director Compensation Policy, meaning they represent routine board compensation rather than an open-market purchase. After this grant, Li directly beneficially owned 1,240,909 Class A shares, in addition to indirect holdings through the Dean Y. Li Revocable Trust, the Dean Y. Li GRAT, and the Dean Y. Li 2021 Family Trust.
Recursion Pharmaceuticals, Inc. reported an insider equity transaction by its Chief Financial Officer on 12/15/2025. The filing shows that 7,057 shares of Class A common stock were disposed of at $4.33 per share. According to the footnote, these shares were withheld by the company to cover tax withholding and remittance obligations related to the net settlement of restricted stock units, rather than an open-market sale.
After this tax withholding event, the reporting person beneficially owned 782,933 shares of Class A common stock directly. The transaction is characterized with code "F," which typically denotes payment of tax liability by withholding securities incident to vesting of equity awards.
Recursion Pharmaceuticals, Inc. (RXRX) Chief Financial Officer reported a routine share withholding related to equity compensation. On 11/25/2025, 2,271 shares of Class A common stock were disposed of in a transaction coded "F" at a price of $4.03 per share. This code indicates shares were withheld by the company to cover tax withholding and remittance obligations arising from the net settlement of restricted stock units.
Following this transaction, the reporting officer beneficially owns 789,990 shares of Class A common stock in direct ownership. No new derivative securities transactions were reported in this filing.
Recursion Pharmaceuticals, Inc. (RXRX) reported an insider transaction by its Chief Financial Officer on Form 4. On 11/17/2025, 11,908 shares of Class A common stock were withheld by the company at a price of $4.14 per share to cover tax obligations from the net settlement of restricted stock units. After this tax withholding, the CFO directly beneficially owns 792,261 shares of Class A common stock.
Recursion Pharmaceuticals, Inc. (RXRX) reported an insider equity transaction by a director and officer (Chief R&D Commercial Officer) on 11/17/2025. The filing shows that 17,584 shares of Class A common stock were disposed of at $4.14 per share under transaction code "F," which indicates shares were withheld by the company to cover tax obligations on the net settlement of restricted stock units.
After this tax withholding event, the reporting person directly beneficially owns 735,538 shares of Class A common stock. The transaction reflects administrative share withholding for taxes rather than an open-market sale.
Recursion Pharmaceuticals (RXRX) CEO/Director Form 4 shows routine equity activity. On 11/17/2025, 40,390 Class A shares were withheld at $4.14 to cover tax obligations from net-settled restricted stock units, leaving 913,839 Class A shares directly owned. On 11/19/2025, the insider converted 40,000 Class B shares into Class A at $0 and sold 40,000 Class A shares at $4.16 under a Rule 10b5-1 trading plan adopted on May 12, 2025, maintaining direct ownership at 913,839 Class A shares.
The insider also reports derivative holdings, including Class B shares convertible into Class A with no expiration date and multiple stock options with exercise prices ranging from $2.48 to $11.40 and expirations extending to 2035. Some Class B holdings are reported indirectly through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust.
Recursion Pharmaceuticals (RXRX) reported an insider equity award on 11/05/2025. A director and officer (Chief R&D Commercial Officer) received 84,925 Class A RSUs at $0 and a stock option for 169,851 shares at an exercise price of $4.96. The RSUs vest 1/16 on February 15, 2026 and every three months thereafter; the option vests 1/48 starting December 5, 2025 with monthly installments thereafter. Following the awards, direct ownership was 753,122 Class A shares.
Recursion Pharmaceuticals (RXRX) CEO and Director reported insider transactions on 11/04/2025 under a Rule 10b5-1 plan adopted May 12, 2025. The filing shows a conversion of 60,000 shares of Class B into Class A at $0 (Code C), a sale of 40,000 Class A shares at $5.21 (Code S), and a gift of 20,000 Class A shares (Code G). Following these transactions, the reporting person directly beneficially owned 954,229 Class A shares. The filing also lists ongoing stock option grants with multi-year vesting schedules.
Recursion Pharmaceuticals (RXRX) CEO and director reported a Form 4 for 10/23/2025. He converted 100,000 shares of Class B into Class A at $0 and sold 100,000 Class A shares at $5.70, pursuant to a Rule 10b5-1 plan adopted on May 12, 2025.
Following these transactions, he directly owned 954,229 Class A shares. The filing also lists remaining Class B holdings and vested/unvested stock options.
Insider transactions at Recursion Pharmaceuticals (RXRX): The CEO and director executed multiple transactions on 10/10/2025 under a Rule 10b5-1 plan adopted May 12, 2025. He acquired 120,000 Class B shares (convertible to Class A) at no cash cost, sold 100,000 Class A shares at $6.04 each, and gifted 20,000 Class A shares. After these moves, the reporting person directly owns 954,229 Class A-equivalent shares.
The filing also lists multiple outstanding stock options totaling significant potential dilution (options for ~3.2M Class A shares listed under different strike prices and vesting schedules) and indirect holdings via LLCs and a family trust. The sale, acquisition and gift were made under the disclosed trading plan and executed on the same date.
Dean Y. Li, a director of Recursion Pharmaceuticals, Inc. (RXRX), acquired 1,961 shares of Class A common stock on 10/01/2025 at a reported price of $0 under the company’s Outside Director Compensation Policy. After the issuance, Mr. Li directly beneficially owns 1,238,528 shares. The filing also discloses indirect holdings: 1,422,048 shares held by the Dean Y. Li Revocable Trust, 136,981 shares held by the Dean Y. Li GRAT, and 421,000 shares held by the Dean Y. Li 2021 Family Trust. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Dar Zavain, a director of Recursion Pharmaceuticals (RXRX), reported acquiring 2,941 shares of Class A common stock on 10/01/2025. The shares were issued $0 under the issuer's Outside Director Compensation Policy. After the transaction, the reporting person beneficially owned 138,758 shares. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 10/03/2025. This filing discloses routine director compensation in equity form.
Christopher Gibson, Chief Executive Officer and Director of Recursion Pharmaceuticals (RXRX), reported transactions dated 09/25/2025. The report shows the acquisition and simultaneous disposition of 100,000 shares of Class A common stock: a conversion/acquisition recorded at $0 and a sale of 100,000 shares at $4.76 per share, reducing his direct beneficial ownership of Class A shares from 1,054,229 to 954,229. The filing states the sale was made pursuant to a Rule 10b5-1 trading plan adopted May 12, 2025. The report also lists indirect holdings through LAHWRAN-3 LLC, LAHWRAN-4 LLC and the Gibson Family Trust, and multiple outstanding stock options and convertible Class B shares that are convertible one-for-one into Class A shares. The form is signed by an attorney-in-fact on 09/26/2025.
Recursion Pharmaceuticals insider transaction: The company's Chief Financial Officer reported a non-derivative transaction in the company's Class A common stock. The filing shows 7,057 shares were withheld as part of net settlement of restricted stock units to satisfy tax withholding at an average price of $4.83 per share, leaving the reporting person with 804,169 shares beneficially owned following the transaction. The filing identifies the transaction as an issuer withholding related to equity compensation rather than an open-market sale.